Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: A critical literature review

Expert Opinion on Drug Safety

Volumn 13, Issue 5, 2014, Pages 605-624

  De Hert, Marc ^a   Detraux, Johan ^a   Peuskens, Joseph ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Hyperprolactinemia; Management; Newly approved APs; Prolactin; Second generation APs; Sexual dysfunctions

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BREXPIPRAZOLE; CARIPRAZINE; CLOZAPINE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AMENORRHEA; CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG FATALITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; LIBIDO DISORDER; MENSTRUATION DISORDER; OLIGOSPERMIA; ORGASM DISORDER; PREVALENCE; PROLACTIN BLOOD LEVEL; QUESTIONNAIRE; RELIABILITY; RETROGRADE EJACULATION; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; VAGINAL DRYNESS; VAGINITIS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; META ANALYSIS; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; HUMANS; PROLACTIN; PSYCHOTIC DISORDERS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84899068297     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.906579     Document Type: Review

References (144)

1. Chiesa A, Leucci V, Serretti A, et al. Antipsychotics and sexual dysfunction: epidemiology, mechanisms and management. Clin Neuropsychia 2013;10(1):31-6
2. Kalkavoura CS, Michopoulos I, Arvanitakis P, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol 2013;21(4):332-41
3. Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003;29(4):289-96
4. Montejo AL, Riesgo Y, Luque J, et al. Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr 2010;38(1):13-21
5. Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive literature review. CNS Drugs 2014, doi: 10.1007/s40263-014-0157-3
6. Kelly DL, Wehring HJ, Earl AK, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry 2013; Published online 22 August 2013, doi: 10.1186/1471-244X-13-214
7. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26(3):130-40
8. Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011;89(1):142-7
9. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19(8)542-50
10. Kropp S, Ziegenbein M, Grohmann R, et al. Galactorrhea due to psychotropic drugs. Pharmacopsychiatry 2004;37(Suppl 1):S84-8
11. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19(2):63-9
12. Malik P, Kemmler G, Hummer M, et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 2011;31(3):274-80
13. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008;23(3):201-9
14. Hanssens L, LItalien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95
15. Ziadi Trives M, Bonete Llacer JM, Garc?a Escudero MA, Mart?nez Pastor CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol 2013;33(4):538-41
16. Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008;22(3):244-53
17. Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health 2012;30(3):153-9
18. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012;6:CD008296
19. Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010;25(6):334-41
20. Montalvo I, Ortega L, Lopez X, et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol 2013;28(1):46-9
21. Montejo Gonzalez AL, Rico-Villademoros F, Tafalla M, et al. A 6 month prospective observational studyon the effects of quetiapine on sexual functioning. J Clin Psychopharmacol 2005;25(6):533-8
22. van Bruggen M, van Amelsvoort T, Wouters L, et al. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology 2009;34(7):989-95
23. Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Res 2008;159(1-2):115-20
24. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31(3):340-6
25. Bobes J, Garc A-Portilla MP, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29(2):125-47
26. Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24(1):56-61
27. Byerly MJ, Nakonezny PA, Bettcher BM, et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006;86(1-3):244-50
28. Konarzewska B, Wo?czynski S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009;34(1):129-39
29. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765-74
30. Muscatello MR, Bruno A, Pandolfo G, et al. Emerging treatments in the management of schizophrenia - focus on sertindole. Drug Des Devel Ther 2010;4:187-201
31. Komossa K, Rummel-Kluge C, Hunger H, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;(2):CD006752
32. Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 2000;4:55-62
33. Montejo AL, Rico-Villademoros F, Spanish Working Group for the Study of Psychotropic Related Sexual Dysfunction. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol 2008;28(5):568-70
34. Nebhinani N, Grover S, Avasthi A. Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire. Prim Care Companion CNS Disord 2012;14(2):PCC.11m01199
35. Lambert M, Haro JM, Novick D, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005;111(3):232-43
36. Mahmoud A, Hayhurst KP, Drake RJ, et al. Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial. Schizophr Res Treatment 2011;2011:596898
37. Mahmoud A, Hayhurst KP, Drake RJ, et al. Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment. Int J Psychiatry Clin Pract 2012;16(2):148-52
38. Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol 2013;6(1):61-91
39. Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses 2012;6(1):34-44
40. Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol 2013;6(1):61-91
41. McIntyre RS, Wong R. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. Clin Schizophr Relat Psychoses 2012;5(4):217-20
42. Szegedi A, Verweij P, van Duijnhoven W, et al. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry 2012;73(12):1533-40
43. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012;13(11):1599-613
44. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013;27(11):879-911.
45. Dainippon Sumitomo Pharma. DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone. News release. 2012. Available from: http://www.dspharma.com/news/ 2012/20121025.html [Last accessed 18 November 2013]
46. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
47. Wang SM, Han C, Lee SJ, et al. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol 2013;36(6):223-38
48. SAPHRIS® (asenapine). Highlights of prescribing information. U.S. Food and Drug Administration. 2013. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2013/022117s012lbl.pdf [Last accessed 12 November 2013]
49. Gonzalez JM, Thompson PM, Moore TA. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 2011;5:333-41
50. Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr 2013;18(1):43-54
51. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2010;64(6):707-18
52. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
53. FANAPT® (iloperidone). Highlights of prescribing information. U.S. Food and Drug Administration. 2013. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2013/022192s007lbl.pdf [Last accessed 12 November 2013]
54. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry 2011;72(Suppl 1):19-23
55. Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm 2011;68(4):301-8
56. LATUDA® (lurasidone). Highlights of prescribing information. U.S. Food and Drug Administration. 2010. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/200603s000lbl.pdf [Last accessed 12 November 2013]
57. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebocontrolled study. Psychopharmacology (Berl) 2013;225(3):519-30
58. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6- week, open-label study. J Clin Psychiatry 2013;74(2):170-9
59. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47(5):670-7
60. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, doubleblind, placebo- and active-controlled trial. Schizophr Res 2013;145(1-3):101-9
61. Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 2008;33(6):711-17
62. Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med 2008;5(12):2816-26
63. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005;66(6):761-7
64. Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol 2010;30(6):711-15
65. Dickson RA, Dalby JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152(7):1102-3
66. Liu-Seifert H, Kinon BJ, Tennant CJ, et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009;5:47-54
67. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(Suppl 2):55-68
68. Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007;33(3):203-16
69. Ali S, Miller KK, Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 2010;51(5):370-6
70. Yasui-Furukori N, Fujii A, Sugawara N, et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol 2012;27(1):82-9
71. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61
72. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15(1):111-17
73. Berry S, Martinez A, Myers J, et al. Serum prolactin in schizophrenia. Poster presented at the 7th World Congress of Biological Psychiatry; 1 - 6 July 2001; Berlin, Germany
74. Kikuchi T, Iwamoto K, Sasada K, et al. Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2012;37(1):26-32
75. Eberhard J, Lindstrom E, Holstad M, et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 2007;115(4):268-76
76. Howes OD, Wheeler MJ, Pilowsky LS, et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 2007;68(3):361-7
77. Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Impot Res 2005;17(2):201-3
78. Lundberg PO, Hulter B. Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol 1991;98(2):81-8
79. Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002;111(1):11-20
80. Smith SM. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 2008;22(2 Suppl):63-9
81. Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(2 Suppl):98-103
82. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2008;22(2 Suppl):90-7
83. Peluso MJ, Lewis SW, Barnes TR, et al. Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1). Schizophr Res 2013;144(1-3):80-6
84. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther 2012;38(3):281-301
85. Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des Devel Ther 2012;6:107-15
86. Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 2012;26(5 Suppl):42-51
87. Reis Marques T, Smith S, Bonaccorso S, et al. Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry 2012;201:131-6
88. Zemishlany Z, Weizman A. The impact of mental illness on sexual dysfunction. Adv Psychosom Med 2008;29:89-106
89. Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry 1998;13(Suppl 1):23s-30s
90. Zhang XR, Zhang ZJ, Zhu RX, et al. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 2011;12(8):1127-36
91. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebocontrolled study using the PRSEXDQSALSEX scale. J Psychopharmacol 2010;24(1):111-20
92. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(Suppl 6):33-7
93. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63(4):357-66
94. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic- Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21
95. Kim S, Park YM. Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotoninreuptake inhibitors: a cross-sectional pilot study. PLoS One 2013;8(12):e82749
96. Schmidt HM, Hagen M, Kriston L, et al. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2012;11:CD003546
97. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-49
98. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80(8):1050-7
99. Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008;18(Suppl 2):S108-14
100. Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ 2003;169(6):575-81
101. Arafah BM, Nekl KE, Gold RS, et al. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 1995;80(12):3507-12
102. Walters J, Jones I. Clinical questions and uncertainty-prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 2008;22(2 Suppl):82-9
103. Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem 2010;47(Pt 4):292-300
104. Ajmal A, Joffe H, Nachtigall LB. Psychotropic-Induced Hyperprolactinemia: a Clinical Review. Psychosomatics 2014;55(1):29-36
105. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138-51
106. Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychoticinduced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;27(6):639-61
107. Knegtering R, Castelein S, Bruggeman R. Vaak seksuele functiestoornissen door antipsychotica, vooral bij prolactineverhoging. Resultaten van een aantal vergelijkende onderzoeken. Tijdschrift Voor Seksuologie 2004;28:140-6
108. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314
109. Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J 2006;124(5):291-7
110. Howes O, Smith S. Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ 2002;324(7348):1278
111. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008;69(Suppl 1):32-44
112. Goffin V, Touraine P, Culler MD, et al. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2006;2(10):571-81
113. La Torre A, Conca A, Duffy D, et al. Sexual Dysfunction Related to Psychotropic Drugs: a Critical Review Part II: antipsychotics. Pharmacopsychiatry 2013;46(6):201-8
114. Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 2008;28(3):264-370
115. CYCLOSET® (bromocriptine mesylate). Highlights of prescribing information. U. S. Food and Drug Administration. 2009. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2009/020866lbl.pdf [Last accessed 12 November 2013]
116. Baeza Pertegaz I, Goikolea Alberdi JM, Parellada Rodon E. Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? J Psychiatry Neurosci 2002;27(1):54
117. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;65(2):187-90
118. Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008;30(4):378-80
119. De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves : metaanalysis of observational studies. Herz 2013;38(8):868-80
120. Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008;31(12):1119-23
121. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009;24(1):129-33
122. Wang D, Wong HK, Zhang L, et al. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychoticassociated hyperprolactinemia. Prog Neuropsychopharmacol Biol Psychiatry 2012;39(2):332-8
123. Tsigkaropoulou E, Peppa M, Zompola C, et al. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gend Med 2012;9(1):56-60
124. Montejo AL, Majadas S, Rico-Villademoros F, et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med 2010;7(10):3404-13
125. Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008;34(3):227-39
126. de Boer MK, Castelein S, Bous J, et al. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity. Schizophr Res 2013;150(2-3):410-15
127. Kikuchi T, Iwamoto K, Sasada K, et al. Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics. Hum Psychopharmacol 2011;26(4-5):300-6
128. Shah SK. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ Med J (KUMJ) 2013;11(42):121-5
129. Chaves KM, Serrano-Blanco A, Ribeiro SB, et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatr Q 2013;84(1):125-35
130. de Boer MK, Wiersma D, Bous J, et al. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J Clin Psychopharmacol 2011;31(4):523-5
131. Fujii A, Yasui-Furukori N, Sugawara N, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(2):288-93
132. Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J Psychiatry 2009;51(4):265-71
133. Perez V, Canas F, Tafalla M, et al. A 12- month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. Int Clin Psychopharmacol 2008;23(3):138-49
134. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164(3):415-27
135. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-22
136. Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 2006;32(4):315-26
137. Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (ICSOHO) study. Eur Psychiatry 2006;21(4):251-8
138. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
139. Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66(3):331-8
140. Dossenbach M, Erol A, el Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004;65(3):312-21
141. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-90
142. Fortier P, Mottard JP, Trudel G, et al. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophr Bull 2003;29(3):559-72
143. Wirshing DA, Pierre JM, Marder SR, et al. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002;56(1-2):25-30
144. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002;63(5):408-13